| DeFronzo, Ralph A |
NCT02911792: Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration |
|
|
| Completed | 4 | 72 | US | Dapagliflozin, Farxiga, Metformin, Metformin-XR, Glipizide 5 MG | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/23 | 07/23 | | |
NCT01107717: Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM |
|
|
| Completed | 4 | 318 | US | metformin\pioglitazone\exenatide, metformin, glyburide and glargine | The University of Texas Health Science Center at San Antonio, American Diabetes Association, Amylin Pharmaceuticals, LLC., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes | 02/23 | 02/23 | | |
|
| Recruiting | 4 | 78 | US | Pioglitazone, Actos, Placebo, Placebo tablet | The University of Texas Health Science Center at San Antonio | Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction | 04/28 | 01/29 | | |
| Recruiting | 1 | 71 | US | Empagliflozin 25 MG Oral Tablet, jardiance, Placebo, Acipimox 250 Mg Oral Capsule | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type2diabetes, Heart Failure With Reduced Ejection Fraction | 11/26 | 03/27 | | |
NCT05093517: Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM |
|
|
| Completed | 1 | 4 | US | REMD-477, Placebo Subcutaneous injection, Placebo | The University of Texas Health Science Center at San Antonio | Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity | 03/22 | 03/22 | | |
NCT05960656: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis |
|
|
| Recruiting | 1 | 169 | US | Empagliflozin 25 MG, Jardiance, Placebo, Placebo for empagliflozin, Pioglitazone 30mg, Actos, Pioglitazone 30mg + Empagliflozin (25 mg), Actos/Jardiance | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes, Type 1 Diabetes | 06/27 | 06/27 | | |
| Completed | 1 | 10 | US | Glucagon Infusion, IV Glucagon, Saline, Normal saline | The University of Texas Health Science Center at San Antonio, South Texas Veterans Health Care System | Insulin Sensitivity | 11/23 | 11/23 | | |
NCT03560323: Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1 |
|
|
| Recruiting | 1 | 78 | US | Beta-hydroxy-butyrate, Infusion of Beta-Hydroxy-Butyrate (B-OH-B) | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Heart Failure, Type 2 Diabetes Mellitus | 10/26 | 02/27 | | |
NCT05057806: SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan |
|
|
| Recruiting | 1 | 30 | US | Empagliflozin 25 MG, Jardiance, Placebo, Placebo for Empagliflozin | The University of Texas Health Science Center at San Antonio, Doris Duke Charitable Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type2 Diabetes, Heart Failure With Preserved Ejection Fraction | 11/26 | 03/27 | | |
NCT03953963: Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes |
|
|
| Recruiting | N/A | 12 | US | HydraSolve T2D™ | Medality Medical | Diabetes Mellitus, Type 2, Insulin Resistance | 07/21 | 03/22 | | |
NCT04791787: Effect of Ketogenic Diet on Glucose Metabolism and Energy Expenditure in Type 2 Diabetes |
|
|
| Completed | N/A | 35 | US | Standard weight maintaining diet, Weight maintaining isocaloric ketogenic diet, Beta-hydroxy butyrate, BHOB | The University of Texas Health Science Center at San Antonio | Glucose Metabolism Disorders (Including Diabetes Mellitus), Energy Supply; Deficiency, Type 2 Diabetes | 04/23 | 04/23 | | |
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) |
|
|
| Recruiting | N/A | 700 | US | Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage | The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) | 03/26 | 07/27 | | |
NCT05867017: Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus |
|
|
| Recruiting | N/A | 213 | US | Measure of physiologic parameters | The University of Texas Health Science Center at San Antonio, National Heart, Lung, and Blood Institute (NHLBI) | COVID-19, Diabete Mellitus | 06/25 | 08/26 | | |
| Cersosimo, Eugenio |
NCT02981966: Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects |
|
|
| Completed | 4 | 32 | US | Dapagliflozin, Farxiga, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 04/22 | 05/23 | | |
NCT02981069: Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM |
|
|
| Completed | 4 | 90 | US | Dapagliflozin, Farxiga, Exenatide, Byetta, Bydureon, Placebo | The University of Texas Health Science Center at San Antonio, AstraZeneca | Diabetes Mellitus, Type 2 | 07/22 | 03/23 | | |
NCT03953963: Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes |
|
|
| Recruiting | N/A | 12 | US | HydraSolve T2D™ | Medality Medical | Diabetes Mellitus, Type 2, Insulin Resistance | 07/21 | 03/22 | | |
NCT02969798: Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) |
|
|
| Recruiting | N/A | 700 | US | Dapagliflozin, farxiga, Saxagliptin, onglyza, Pioglitazone, actos, Metformin, glucophage | The University of Texas Health Science Center at San Antonio, American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG) | 03/26 | 07/27 | | |
| Abdul-Ghani, Muhammad |
| Completed | 4 | 72 | US | Empagliflozin 25 MG, Control, Placebo | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Hepatic Glucose Metabolism | 01/23 | 01/24 | | |
| Recruiting | 4 | 120 | US, RoW | Pioglitazone 45 mg, Placebo | The University of Texas Health Science Center at San Antonio | Type 1 Diabetes Mellitus | 12/24 | 01/25 | | |
NCT06246799: Comparative Effectiveness of Two Initial Combination Therapies in Patients with Recent Onset Diabetes |
|
|
| Recruiting | 3 | 730 | US | Tirzepatide, Mounjaro, Pioglitazone, Actos, Sitagliptin, Januvia, Metformin HCI XR, Extended Release Metformin | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes (Adult Onset) | 04/29 | 06/29 | | |
| Patel, Sandeep |
| Active, not recruiting | N/A | 44467 | US | | Guardant Health, Inc., Premier Research Group plc | Colorectal Cancer | 03/24 | 12/25 | | |
| Chen, Stephen |
NCT05093517: Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM |
|
|
| Completed | 1 | 4 | US | REMD-477, Placebo Subcutaneous injection, Placebo | The University of Texas Health Science Center at San Antonio | Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity | 03/22 | 03/22 | | |
| Recruiting | N/A | 114 | US, RoW | GPX® Embolic Device | Fluidx Medical Technology, Inc., Bright Research Partners | Embolism, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma, Bone Tumor, Portal Vein Embolism | 05/26 | 09/26 | | |
